[Memorandum to Presidential Advisory Council on HIV and AIDS Research Committee Members from Bruce G. Weniger]

PACHA Research Committee - 17-Jan-97 Conference Call - p. 2
Dr. Moss, of the Immune Response Corporation, is the
first informant in our series to request to address the
Council, rather than be invited. As his biotechnology
company is currently only pursuing a therapeutic vaccine
for persons already infected, I explained our focus on
preventive vaccines. He promised to provide as much
experience and insight into the obstacles and impediments
and solutions for that kind of vaccine, and to minimize
technical details about the performance of his company's
therapeutic product. He also pledged that the opportunity
to address the Committee would not be actively announced by
his company for public relations purposes. Dr. Moss has
provided a written statement to accompany his oral
presentation. This is included at the end of the faxed
version of this memo.
In addition, but not on the call, Professor Raymond E.
Spier, submitted to me a written statement and an editorial
to add to our collection in the Committee archives. This,
too, is attached at the end of this fax. Dr. Spier is the
editor of the journal Vaccine, and a professor of
microbiology at the University of Surrey, UK. He has
experience in virus vaccine production at Merck, Sharpe and
Dohme, and since 1973 has been involved in virus vaccine
research in the United Kingdom.
SCHEDULE Friday, 17 January 1997
(All times Eastern Standard)
9:55 - 10:00 AM Committee Housekeeping; Announcements
10:00 - 10:30 DAVID BALTIMORE, PhD
A distinguished molecular biologist
with over 500 scientific publications.
Discoverer of the reverse transcriptase
enzyme/gene for which he was awarded the
Nobel Prize in Medicine or Physiology.
Former President of Rockefeller University,
and now I.R. Cottrell Professor of Molecular
Biology and Immunology at MIT. Designated